Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) begins as simple hepatic steatosis, but further progress to chronic liver diseases results in severe liver damage and hepatic failure. However, therapeutic options are scarce due to the lack of reliable human in vitro liver models for understandi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Jae-Sung, Lee, Minji, Mun, Seon Ju, Hong, Sin-Hyoung, Lee, Ho-Joon, Ahn, Hyo-Suk, Chung, Kyung-Sook, Kim, Gun-Hwa, Son, Myung Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686528/
https://www.ncbi.nlm.nih.gov/pubmed/31406506
http://dx.doi.org/10.1186/s13036-019-0198-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686528/
https://www.ncbi.nlm.nih.gov/pubmed/31406506
http://dx.doi.org/10.1186/s13036-019-0198-8

Ejemplares similares